Trial Details

Not Recruiting
Basic Information
Clinical ID c2725
Identifier CTRI/2018/10/015908
Trial Title A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis__LUCENT 1__ - LUCENT 1
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Health Condition 1: K519- Ulcerative colitis, unspecified__
Interventions Intervention1: blinded intravenous administration of 300 mg mirikizumab: Patients will be randomized with 3:1 ratio to receive blinded Intravenous Administration Duration of treatment with the investigational product is 12 weeks. Intervention2: Experimental Mirikizumab administered intravenously (IV): Drug: Mirikizumab Administered IV Control Intervention1: placebo Patients will be randomized with 3:1 ratio to receive blinded Intravenous Administration of: every 4 weeks at Weeks 0, 4, and 8 Duration of treatment with the investigational product is 12 weeks Control Intervention2: Placebo Comparator: Placebo administered IV. : Drug: Placebo Administered IV
Participant Information
Sponsor Eli Lilly and Company Lilly
City -
Country/Region Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Ireland;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Republic of Korea;Romania;Russia;Saudi Arabia;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
Enrollment Criteria
Sex Requirement NOT SPECIFIED
Age Requirement -
Study Design
Study Type Interventional
Phase PHASE3
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -